About aglasidase beta
Enzyme replacement therapy
Used for
- Long-term enzyme replacement for Fabry disease.
Usual adult dose
1 mg/kg by intravenous infusion every 2 weeks.
Usual dose in children
1 mg/kg by intravenous infusion every 2 weeks; approved for children aged 8 years and older.
Common side effects
- Infusion reactions, including fever, chills, headache, nausea, or flushing
- Pain or discomfort in the limbs
- Antibodies to the medicine
Important warnings
- Infusion reactions can be severe, including allergic reactions.
- Kidney, heart, and breathing complications may occur during infusion reactions.
- Patients can develop antibodies that may affect treatment response.
Pregnancy
Use only when clearly needed; human pregnancy data are limited.
Breastfeeding
Unknown whether it passes into breast milk; use requires consideration of benefits and risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.